3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
71
CNS
3
Gastrointestinal
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Endocrine
1
Conditions
Thyroid Neoplasms
5
Thyroid Cancer, Papillary
4
Thyroid Carcinoma, Anaplastic
2
Thyroid cancer, follicular
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Heterotaxy Syndrome
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma, Follicular
1
Interventions
pembrolizumab
73
Nivolumab
27
atezolizumab
15
Docetaxel
10
Cyclophosphamide
10
cemiplimab
9
Ipilimumab
9
Paclitaxel
8
Interleukin-2
8
Biopsy
7
fludarabine
6
durvalumab
6
avelumab
6
Taxes
6
Specimen Handling
6
epacadostat
5
Magnetic Resonance Spectroscopy
5
Immune Checkpoint Inhibitors
5
Gemcitabine
5
Drug Therapy
5
Cisplatin
5
Carboplatin
5
spartalizumab
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
Cetuximab
4
utomilumab
3
trametinib
3
poly ICLC
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Vemurafenib
×
Head & Neck
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled